FindTrial
Sign In

Clinical application of exosomal DNA as a ''liquid biopsy'' marker for whole-process monitoring of liver cancer

Clinical application of exosomal DNA as a ''liquid biopsy'' marker for whole-process monitoring of liver cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100054275
Enrollment
Unknown
Registered
2021-12-12
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic cancer

Interventions

Gold Standard:Pathological diagnosis, clinical outcome
Index test:Exosomal DNA

Sponsors

The Second Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Untreated HCC patients with indications for surgery; 2. Fully understand this project, agree to enroll and be willing to undergo surgical treatment; 3. There is no obvious contraindication to surgery.

Exclusion criteria

Exclusion criteria: 1. Have a medical history of intervention, targeted drugs, etc. before enrollment; 2. Patients who cannot provide follow-up information.

Design outcomes

Primary

MeasureTime frame
Exosomal DNA;Diagnostic effectiveness evaluation;Prognostic efficacy evaluation;Treatment effect;—

Countries

China

Contacts

Public ContactLiao Wenjun

The Second Affiliated Hospital of Nanchang University

Liaowenjun120@163.com+86 13870633069

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026